Oncology Institute, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $502.7M | $393.4M | $324.2M | $252.5M | $203.0M |
| Selling, general & administrative | $105.6M | $107.8M | $113.9M | $119.7M | $83.4M |
| Operating income | -$36.1M | -$60.1M | -$77.0M | -$82.0M | -$45.9M |
| Interest expense | $11.3M | $7.5M | $6.8M | — | $320,000 |
| Pretax income | -$60.7M | -$64.7M | -$83.1M | -$91,000 | -$11.6M |
| Income tax expense | -$131,000 | $0 | -$36,000 | -$243,000 | -$671,000 |
| Net income | -$60.6M | -$64.7M | -$83.1M | $152,000 | -$10.9M |
| Balance Sheet | |||||
| Current assets | $112.7M | $112.4M | $143.5M | $130.4M | $154.1M |
| Total assets | $164.7M | $172.7M | $209.2M | $261.7M | $203.4M |
| Current liabilities | $71.0M | $52.2M | $34.8M | $29.7M | $29.8M |
| Total liabilities | $180.4M | $169.1M | $152.2M | $138.5M | $99.3M |
| Total debt | $85.9M | $110.0M | $110.0M | $110.0M | — |
| Stockholders' equity | -$15.7M | $3.6M | $57.0M | $123.2M | $104.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$24.6M | -$26.5M | -$36.3M | -$61.8M | -$32.7M |
| Depreciation and amortization | $6.9M | $6.3M | $5.9M | $4.4M | $3.3M |
| Stock-based compensation | $4.6M | $11.2M | $17.8M | $27.7M | $24.5M |
| Capital expenditure | $3.2M | $3.8M | $4.6M | $5.5M | $2.8M |
| Free cash flow | -$27.8M | -$30.3M | -$40.9M | -$67.3M | -$35.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Share repurchases | — | $0 | $1.0M | $9.0M | $0 |
| Impairments | $0 | $0 | $16.9M | $9.9M | $0 |
Shares outstanding 100.0M · Free float 51.0%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.